Teva Exits Japanese Generics With Plan To Sell Local Business
Firm Registers Impairment Charge Of Almost $600m As Unit Is Classified As Held-For-Sale
Teva is putting its Japanese generics business up for sale, in an exit from the country’s generics market that has led the Israeli firm to register a substantial impairment charge in Q1.
